REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 174 filers reported holding REATA PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $34,747,254 | +12.1% | 340,793 | 0.0% | 0.15% | +17.3% |
| Q1 2023 | $30,984,900 | +139.3% | 340,793 | 0.0% | 0.13% | +159.2% |
| Q4 2022 | $12,946,726 | +151076.2% | 340,793 | 0.0% | 0.05% | +53.1% |
| Q3 2022 | $8,564 | -99.9% | 340,793 | 0.0% | 0.03% | -5.9% |
| Q2 2022 | $10,357,000 | -7.2% | 340,793 | 0.0% | 0.03% | +21.4% |
| Q1 2022 | $11,164,000 | +24.2% | 340,793 | 0.0% | 0.03% | +21.7% |
| Q4 2021 | $8,987,000 | -73.8% | 340,793 | 0.0% | 0.02% | -69.7% |
| Q3 2021 | $34,287,000 | -28.9% | 340,793 | 0.0% | 0.08% | -30.3% |
| Q2 2021 | $48,232,000 | +42.0% | 340,793 | 0.0% | 0.11% | +60.3% |
| Q1 2021 | $33,977,000 | -19.4% | 340,793 | 0.0% | 0.07% | -54.1% |
| Q4 2020 | $42,129,000 | +81.3% | 340,793 | +42.9% | 0.15% | +64.4% |
| Q3 2020 | $23,240,000 | -46.6% | 238,555 | -14.5% | 0.09% | -51.1% |
| Q2 2020 | $43,543,000 | – | 279,085 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
| CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
| Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
| DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
| MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
| Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
| Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
| Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |